Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate... by Schütt, P, Ebeling, P, Buttkereit, U, Brandhorst, D, Opalka, B, Poser, M, Müller, S, Flasshove, M, Moritz, T, Seeber, S, Nowrousian, MR

Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma. by Schütt, P, Ebeling, P, Buttkereit, U, Brandhorst, D, Opalka, B, Hoiczyk, M, Flasshove, M, Hense, J, Bojko, P, Metz, K, Moritz, T, Seeber, S, Nowrousian, MR

Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. by Nowrousian, MR, Brandhorst, D, Sammet, C, Kellert, M, Daniels, R, Schuett, P, Poser, M, Mueller, S, Ebeling, P, Welt, A, Bradwell, A, Buttkereit, U, Opalka, B, Flasshove, M, Moritz, T, Seeber, S

Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma by Nowrousian, MR, Brandhorst, D, Sammet, C, Kellert, M, Daniels, R, Schuett, P, Poser, M, Mueller, S, Ebeling, P, Welt, A, Bradwell, A, Buttkereit, U, Opalka, B, Flasshove, M, Moritz, T, Seeber, S